keyword
MENU ▼
Read by QxMD icon Read
search

New antidepressants

keyword
https://www.readbyqxmd.com/read/29775613/suppression-of-nlrp3-inflammasome-attenuates-stress-induced-depression-like-behavior-in-nlgn3-deficient-mice
#1
Ze-Qun Li, Zhi-Yuan Yan, Bo-Jun Lan, Yi-Qun Dong, Ye Xiong
Depression, regulated by central nervous system (CNS), is a significant inflammatory disorder. Neuroligin3 (NLGN3) has been implicated in brain functions. In the study, a chronic unpredictable mild stress (CUMS) model in wild type (WT) or NLGN3-knockout (KO) mice was established to explore the role of NLGN3 in regulating depression and to reveal the underlying molecular mechanism. The results indicated that NLGN3-knockout markedly reversed the loss of body weight, the reduction of sucrose consumption, the decrease of immobile time in the forced swimming tests (FST) and tail suspension tests (TST) induced by CUMS paradigm...
May 15, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29763648/autism-spectrum-disorder-classification-diagnosis-and-therapy
#2
REVIEW
Samata R Sharma, Xenia Gonda, Frank I Tarazi
Autism Spectrum Disorder (ASD) refers to a group of neurodevelopmental disorders including autism, Asperger's syndrome (AS) and pervasive developmental disorder-not otherwise specified (PDD-NOS). The new diagnostic criteria of ASD focuses on two core domains: social communication impairment and restricted interests/repetitive behaviors. The prevalence of ASD has been steadily increasing over the past two decades, with current estimates reaching up to 1 in 36 children. Hereditary factors, parental history of psychiatric disorders, pre-term births, and fetal exposure to psychotropic drugs or insecticides have all been linked to higher risk of ASD...
May 12, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29760569/concomitant-use-of-opioid-medications-with-triptans-or-serotonergic-antidepressants-in-us-office-based-physician-visits
#3
Kyle C Molina, Kathleen A Fairman, David A Sclar
Background: Opioids are not recommended for routine treatment of migraine because their benefits are outweighed by risks of medication overuse headache and abuse/dependence. A March 2016 US Food and Drug Administration (FDA) safety communication warned of the risk of serotonin syndrome from using opioids concomitantly with 5-hydroxytryptamine receptor agonists (triptans) or serotonergic antidepressants: selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)...
2018: Drug, Healthcare and Patient Safety
https://www.readbyqxmd.com/read/29756288/mixed-states-in-bipolar-and-major-depressive-disorders-systematic-review-and-quality-appraisal-of-guidelines
#4
REVIEW
N Verdolini, D Hidalgo-Mazzei, A Murru, I Pacchiarotti, L Samalin, A H Young, E Vieta, A F Carvalho
OBJECTIVE: This systematic review provided a critical synthesis and a comprehensive overview of guidelines on the treatment of mixed states. METHOD: The MEDLINE/PubMed and EMBASE databases were systematically searched from inception to March 21st, 2018. International guidelines covering the treatment of mixed episodes, manic/hypomanic, or depressive episodes with mixed features were considered for inclusion. A methodological quality assessment was conducted with the Appraisal of Guidelines for Research and Evaluation-AGREE II...
May 13, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29755551/antidepressant-like-effect-of-a-chalcone-compound-dhipc-and-its-possible-mechanism
#5
Dong-Hai Zhao, Yan-Chun Wang, Lian-Wen Zheng, Bing-Yu Liu, Li-Ping Guan
DHIPC (2,4-dichloro-2´-hydroxyl-4´,6´-diisoprenyloxychalcone) is a new chalcone compound. In this study, its antidepressant-like activity of compound DHIPC was evaluated by the forced swimming test and the tail suspension test in mice. The results showed that DHIPC significantly reduced the immobility time for 2 h after treatment through the oral administration at dose of 10, 20, and 30 mg/kg in the forced swimming test and the tail suspension test, indicating a significant antidepressant-like effect. The maximal effect was obtained at 30 mg/kg, which is similar to the positive control fluoxetine...
2018: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/29753639/nrem-parasomnias-a-treatment-approach-based-upon-a-retrospective-case-series-of-512-patients
#6
Panagis Drakatos, Lucy Marples, Rexford Muza, Sean Higgins, Nadia Gildeh, Raluca Macavei, Eptehal M Dongol, Alexander Nesbitt, Ivana Rosenzweig, Elaine Lyons, Grainne d'Ancona, Joerg Steier, Adrian J Williams, Brian D Kent, Guy Leschziner
BACKGROUND: Non-REM parasomnias are not uncommon conditions in the general population. Current treatment options are based on small case series and reports. In this study, we aimed to present the clinical experience from a large cohort of patients. PATIENTS: Five hundred and twelve patients with Non-REM parasomnia or parasomnia overlap disorder (POD), who had undergone a video polysomnography and were exposed to treatment, were retrospectively identified. Treatment outcome was assessed based on patients' reports, and treatment approach on a locally accepted hierarchy of interventions...
April 10, 2018: Sleep Medicine
https://www.readbyqxmd.com/read/29751080/prenylated-%C3%AE-diketones-two-new-additions-to-the-family-of-biologically-active-hypericum-perforatum-l-hypericaceae-secondary-metabolites
#7
Niko S Radulović, Marija S Genčić, Nikola M Stojanović, Pavle J Randjelović, Nicolas Baldovini, Vanya Kurteva
Two novel β-diketones, 2,6,9-trimethyl-8-decene-3,5-dione (A) and 3,7,10-trimethyl-9-undecene-4,6-dione (B), were identified from the renowned medicinal plant Hypericum perforatum L. The structures of β-diketones A and B were corroborated by syntheses (4 steps starting from methyl acetoacetate, overall yields 30% and 23%, respectively). In solution, these β-diketones predominantly exist as two rapidly interconverting β-keto-enol tautomers. The structures of A and B show some common fragments with the molecules of hyperforin and adhyperforin, respectively, the acknowledged multi-target secondary metabolites from St...
May 8, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29747564/reduse-reducing-antipsychotic-and-benzodiazepine-prescribing-in-residential-aged-care-facilities
#8
Juanita L Westbury, Peter Gee, Tristan Ling, Donnamay T Brown, Katherine H Franks, Ivan Bindoff, Aidan Bindoff, Gregory M Peterson
OBJECTIVE: To assess the impact of a multi-strategic, interdisciplinary intervention on antipsychotic and benzodiazepine prescribing in residential aged care facilities (RACFs). Design, setting: Prospective, longitudinal intervention in Australian RACFs, April 2014 - March 2016. PARTICIPANTS: 150 RACFs (with 12 157 residents) comprised the main participant group; two further groups were consultant pharmacists (staff education) and community pharmacies (prescribing data)...
May 14, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29744362/antioxidant-hepatoprotective-and-antidepression-effects-of-rumex-tingitanus-extracts-and-identification-of-a-novel-bioactive-compound
#9
Dhekra Mhalla, Karama Zouari Bouassida, Rachid Chawech, Amira Bouaziz, Samar Makni, Lobna Jlaiel, Slim Tounsi, Raoudha Mezghani Jarraya, Mohamed Trigui
Over the last few decades, Rumex species have been recognized as a promising source of new compounds with numerous pharmacological activities. Therefore, the antioxidant activity of Rumex tingitanus (R. tingitanus) leaves extracts was evaluated in vitro and then confirmed in vivo as well as the antidepressant-like and toxicological effects of the extracts. The ethyl acetate fraction (Rt EtOAcF) followed by hydroalcoholic extract (Rt EtOH-H2 O) showed a remarkable in vitro antioxidant activity. The hydroalcoholic extract (Rt EtOH-H2 O) showed significant hepatoprotective activity against carbon tetrachloride- (CCl4 -) induced liver toxicity which is seen from inhibition of the malondialdehyde (MDA) accumulation and enhancement of the liver antioxidant enzymes activities...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29740748/the-effects-of-chronic-amitriptyline-on-zebrafish-behavior-and-monoamine-neurochemistry
#10
Darya A Meshalkina, Elana V Kysil, Kristina A Antonova, Konstantin A Demin, Tatiana O Kolesnikova, Sergey L Khatsko, Raul R Gainetdinov, Polina A Alekseeva, Allan V Kalueff
Amitriptyline is a commonly used tricyclic antidepressant (TCA) inhibiting serotonin and norepinephrine reuptake. The exact CNS action of TCAs remains poorly understood, necessitating new screening approaches and novel model organisms. Zebrafish (Danio rerio) are rapidly emerging as a promising tool for pharmacological research of antidepressants, including amitriptyline. Here, we examine the effects of chronic 2-week exposure to 10 and 50 μg/L amitriptyline on zebrafish behavior and monoamine neurotransmitters...
May 8, 2018: Neurochemical Research
https://www.readbyqxmd.com/read/29736027/antidepressive-effects-of-targeting-elk-1-signal-transduction
#11
Kallia Apazoglou, Séverine Farley, Victor Gorgievski, Raoul Belzeaux, Juan Pablo Lopez, Julien Grenier, El Chérif Ibrahim, Marie-Anne El Khoury, Yiu C Tse, Raphaele Mongredien, Alexandre Barbé, Carlos E A de Macedo, Wojciech Jaworski, Ariane Bochereau, Alejandro Orrico, Elsa Isingrini, Chloé Guinaudie, Lenka Mikasova, Franck Louis, Sophie Gautron, Laurent Groc, Charbel Massaad, Ferah Yildirim, Vincent Vialou, Sylvie Dumas, Fabio Marti, Naguib Mechawar, Elise Morice, Tak P Wong, Jocelyne Caboche, Gustavo Turecki, Bruno Giros, Eleni T Tzavara
Depression, a devastating psychiatric disorder, is a leading cause of disability worldwide. Current antidepressants address specific symptoms of the disease, but there is vast room for improvement 1 . In this respect, new compounds that act beyond classical antidepressants to target signal transduction pathways governing synaptic plasticity and cellular resilience are highly warranted2-4 . The extracellular signal-regulated kinase (ERK) pathway is implicated in mood regulation5-7 , but its pleiotropic functions and lack of target specificity prohibit optimal drug development...
May 7, 2018: Nature Medicine
https://www.readbyqxmd.com/read/29730027/synthesis-and-activity-of-di-or-trisubstituted-n-phenoxyalkyl-or-n-2-2-phenoxy-ethoxy-ethyl-piperazine-derivatives-on-the-central-nervous-system
#12
Katarzyna Pańczyk, Karolina Pytka, Magdalena Jakubczyk, Anna Rapacz, Kinga Sałat, Anna Furgała, Agata Siwek, Monika Głuch-Lutwin, Anna Gryboś, Karolina Słoczyńska, Elżbieta Pękala, Paweł Żmudzki, Adam Bucki, Marcin Kołaczkowski, Dorota Żelaszczyk, Henryk Marona, Anna M Waszkielewicz
Aim of the study was evaluation of anxiolytic, antidepressant, anticonvulsant and analgesic activity in a series of a consistent group of compounds. A series of eleven new N-(phenoxyalkyl)- or N-{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives has been obtained. Their affinity towards 5-HT1A , 5-HT2A , 5-HT6 , 5-HT7 , D2 and α1 receptors has been assessed, and then functional assays were performed. The compounds were evaluated in mice, i.p. for their antidepressant-like (forced swim test), locomotor, anxiolytic-like (four-plate test) activities as well as - at higher doses - for anticonvulsant potential (MES) and neurotoxicity (rotarod)...
April 25, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29726758/pharmacotherapy-for-the-treatment-of-depression-in-patients-with-alzheimer-s-disease-a-treatment-resistant-depressive-disorder
#13
Madia Lozupone, Maddalena La Montagna, Francesca D'Urso, Carla Piccininni, Rodolfo Sardone, Vittorio Dibello, Gianluigi Giannelli, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Nicola Quaranta, Davide Seripa, Antonello Bellomo, Giancarlo Logroscino, Francesco Panza
Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. Areas covered: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs)...
May 4, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29723763/behavioral-activation-therapy-during-transcranial-magnetic-stimulation-for-major-depressive-disorder
#14
Grace B Russo, Eric Tirrell, Andrew Busch, Linda L Carpenter
BACKGROUND: Behavioral Activation (BA) Therapy and Transcranial Magnetic Stimulation (TMS) have each been shown to be effective in the treatment of adult outpatients with major depressive disorder (MDD). Combining both treatments may produce synergistic antidepressant outcomes. METHODS: We developed a new protocol for incorporating a simplified version of BA during a standard 6-week course of TMS and it was pilot tested in 11 consecutively treated outpatients with treatment resistant depression (TRD)...
April 25, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29720938/isolation-and-characterization-of-two-new-secondary-metabolites-from-quercus-incana-and-their-antidepressant-and-anxiolytic-like-potential
#15
Rizwana Sarwar, Umar Farooq, Sadia Naz, Ajmal Khan, Syed M Bukhari, Haroon Khan, Nasiara Karim, Imran Khan, Ayaz Ahmed, Ahmed Al-Harrasi
The ethyl acetate fraction of Quercus incana yielded two new compounds [ 1 and 2 ]. The characterization and structure elucidation of these compounds were carried out through various spectroscopic techniques such as mass spectrometry along with one- and two-dimensional NMR techniques. The structural formula was deduced to be 2-(4-hydroxybutan-2-yl)-5-methoxyphenol [ 1 ] and 4-hydroxy-3-(hydroxymethyl) pentanoic acid [ 2 ]. The elevated plus maze (EPM) and light-dark box (LDB) tests (classical mouse models) were performed in order to reveal the anxiolytic potential of both compounds [ 1 and 2 ]...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29719344/meta-analysis-of-the-efficacy-and-safety-of-repetitive-transcranial-magnetic-stimulation-rtms-in-the-treatment-of-depression
#16
REVIEW
Yanyan Wei, Junjuan Zhu, Shengke Pan, Hui Su, Hui Li, Jijun Wang
Background: Repetitive transcranial magnetic stimulation (rTMS) is a new type of physiotherapy technology that has been widely used in the research of depression. Although many clinical trials have found that compared to the placebo interventions, rTMS has a significant effect on the improvement of depressive symptoms, the outcomes remain inconsistent due to differences in rTMS treatment frequency, parameter settings, and site for stimulation. Aims: This study systematically evaluated the safety and efficacy of rTMS combined with antidepressants for the treatment of depression in Chinese and English randomized, double-blind and sham controlled trials and explored the possible related factors affecting the efficacy and safety...
December 25, 2017: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/29718013/ketamine-for-treatment-resistant-depression-a-new-advocate
#17
Rodrigo Pérez-Esparza
Current alternatives for the treatment of major depressive disorder lack efficacy and have a delayed onset of action. Recently, the glutamatergic neurotransmission system has been noted to play an important role in the pathophysiology of this disorder. Ever since the first report of the antidepressant effects of the N-methyl-D-aspartate receptor antagonist, ketamine, research has been redirected to novel therapeutic targets. With this rapidly growing evidence of a fast-acting antidepressant such as ketamine, as well as its efficacy in treatment-resistant cases of depression, off-label use has become popular in certain settings...
2018: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
https://www.readbyqxmd.com/read/29715490/an-antidepressant-related-pharmacological-signature-for-positive-allosteric-modulators-of-%C3%AE-2-3-containing-gaba-a-receptors
#18
K R Methuku, X Li, R Cerne, S D Gleason, J M Schkeryantz, V V N P B Tiruveedhula, L K Golani, G Li, M M Poe, Md T Rahman, J M Cook, J L Fisher, J M Witkin
Data from transgenic animals and novel pharmacological agents has realigned scientific scrutiny on the therapeutic potential of positive allosteric modulators (PAMs) of α2/3-containing GABAA receptors. Evidence for analgesic, anticonvulsant, and anxiolytic activity of α2/3-selective PAMs has been presented along with the clinical potential for a milder motor-impacting profile compared to non-selective GABAA receptor PAMs. A new series of α2/3-selective PAMs was recently introduced which has anxiolytic and anticonvulsant activity in rodent models...
April 28, 2018: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/29714004/non-bleeding-adverse-events-with-the-use-of-direct-oral-anticoagulants-a-sequence-symmetry-analysis
#19
Géric Maura, Cécile Billionnet, Joël Coste, Alain Weill, Anke Neumann, Antoine Pariente
INTRODUCTION: Postmarketing pharmacovigilance reports have raised concerns about non-bleeding adverse events associated with direct oral anticoagulants (DOACs), but only limited results are available from large claims databases. OBJECTIVE: The aim of this study was to assess the potential association between DOAC initiation and the onset of four types of non-bleeding adverse events by sequence symmetry analysis (SSA). METHODS: SSA was performed using nationwide data from the French National Healthcare databases (Régime Général, 50 million beneficiaries) to assess a cohort of 386,081 DOAC new users for the first occurrence of four types of non-bleeding outcomes: renal, hepatic, skin outcomes identified by using hospitalization discharge diagnoses, and gastrointestinal outcomes by using medication reimbursement...
April 30, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29705602/liraglutide-attenuates-the-depressive-and-anxiety-like-behaviour-in-the-corticosterone-induced-depression-model-via-improving-hippocampal-neural-plasticity
#20
Han Weina, Niu Yuhu, Holscher Christian, Li Birong, Shen Feiyu, Wang Le
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk factor of psychiatric diseases. This relationship opens the opportunity to develop new antidepressant drugs by repurposing antidiabetic drugs. Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. In addition, the GLP-1 analog liraglutide has been shown to promote neurogenesis, which is seen to play important roles in memory formation and cognitive and emotional processing...
April 26, 2018: Brain Research
keyword
keyword
12253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"